Dzhintropin - instructions for use, reviews, analogs and forms of release (injections in ampoules for subcutaneous administration of 4 IU and 10 IU) of a drug for the treatment of growth retardation and somatropin hormone deficiency in adults, children and in pregnancy

In this article, you can read the instructions for using the drug Gentropine. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Dzhintropina in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Gintropin in the presence of existing structural analogues.Use to treat growth retardation and hormone deficiency of somatropin in adults, children, as well as in pregnancy and lactation.

Gentropine - is a genetically engineered growth hormone. Stimulates skeletal and somatic growth, and also has a pronounced effect on metabolic processes. Stimulates the growth of the bones of the skeleton, affecting the plate epiphysis tubular bones, bone metabolism. Helps normalize body structure by increasing muscle mass and reducing body fat. In patients with growth hormone deficiency and osteoporosis, substitution therapy leads to normalization of mineral composition and bone density. Increases the number and size of cells of muscles, liver, thymus gland, gonads, adrenals, thyroid gland. Stimulates the transport of amino acids into the cell and the synthesis of proteins, lowers cholesterol, affecting the profile of lipids and lipoproteins. Suppresses the release of insulin. Promotes the retention of sodium, potassium and phosphorus. Increases body weight, muscle activity and physical endurance.

Composition

Somatropin + auxiliary substances.

Pharmacokinetics

The absorption of somatropin after subcutaneous administration is 80%. Penetrates into well-perfused organs. Metabolized in the kidneys and liver. It is excreted by the kidneys and with bile (including 0.1% unchanged).

Indications

• growth retardation in children due to inadequate growth hormone secretion, gonadal dysgenesis (Shereshevsky-Turner syndrome), chronic renal failure (decrease in kidney function by more than 50%) in the prepubertal period;
• in adults with confirmed congenital or acquired growth hormone deficiency as a replacement therapy.

Forms of release

Lyophilizate for the preparation of a solution for subcutaneous administration of 4 IU and 10 IU (injections in ampoules for injection).

Instructions for use and dosage

Dzhintropin injected subcutaneously, slowly, 1 time per day, usually at night. It is necessary to change the injection site to prevent the development of lipoatrophy.

Dissolve the contents of the vial is recommended in 1 ml of the supplied solvent, based on the calculated dose. To do this, take the solvent with a syringe and inject it into the vial with the drug through a stopper. Gently shake until the contents of the vial are completely dissolved. Sharp shaking is unacceptable.The prepared solution is stored in the vial for no more than two weeks at a temperature of 2 ° C to 8 ° C.

Doses are selected individually, taking into account the severity of growth hormone deficiency, mass or body surface area, the effectiveness in the therapy process.

In children with insufficient growth hormone secretion, a dose of 25-35 μg / kg per day (0.07-0.1 IU / kg per day) is recommended, which corresponds to 0.7-1 mg / m2 per day (2-3 IU / m2 per day). Treatment begins as early as possible and continues until puberty and / or until the bone growth zones are closed. It is possible to stop treatment when the desired result is achieved.

With the Shereshevsky-Turner syndrome, with chronic renal failure in children accompanied by growth retardation, a dose of 50 μg / kg per day (0.14 IU / kg per day) is recommended, which corresponds to 1.4 mg / m2 per day (4.3 IU / m2 per day). If the dynamics of growth is insufficient, a dose adjustment may be required.

With a deficiency of growth hormone in adults, the initial dose is 0.15-0.3 mg per day (corresponding to 0.45-0.9 IU per day) with subsequent increase, depending on the effect.

When the dose is titrated, the level of insulin-like growth factor 1 (IRP-1) in the blood serum can be used as a control parameter.The maintenance dose is selected individually, but does not exceed, as a rule, 1 mg per day, which corresponds to 3 IU per day.

Elderly patients are recommended lower doses.

Side effect

• increased intracranial pressure (headache, nausea, vomiting, impaired vision);
• decreased thyroid function;
• hyperglycemia;
• leukemoid reactions;
• epiphysis of the head of the femur;
• fluid retention with development of peripheral edema;
• arthralgia;
• myalgia;
• tunnel syndrome;
• skin rash;
• itching;
• the formation of antibodies to the drug with a decrease in its effectiveness;
• hyperemia, swelling, pain, itching at the injection site;
• weakness;
• fatigue;
• gynecomastia;
• edema of the optic disc (usually observed during the first 8 weeks of treatment, most often in patients with Shereshevsky-Turner syndrome);
• pancreatitis (abdominal pain, nausea, vomiting);
• otitis media and hearing impairment (in patients with Shereshevsky-Turner syndrome);
• subluxation of the hip in children (limping, pain in the thigh and knee);
• acceleration of the growth of the previously existing nevus (malignancy is possible);
• progression of scoliosis (in patients with excessively rapid growth);
• an increase in the content in the blood of inorganic phosphate, parathyroid hormone and activity of AP.

Contraindications

• malignant neoplasms;
• active brain tumors;
• Urgent conditions (including conditions after operations on the heart, abdominal cavity, acute respiratory failure);
• pregnancy;
• the period of breastfeeding (during the period of treatment it is necessary to refuse breastfeeding);
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Contraindicated in pregnancy and lactation.

special instructions

Against the backdrop of treatment with Jintropin, dosage adjustment of hypoglycemic drugs in diabetic patients may be required, manifestation of latent hypothyroidism may occur, and in patients receiving thyroxine, signs of hyperthyroidism may appear.

During treatment, it is necessary to monitor the condition of the fundus, especially with symptoms of intracranial hypertension. Edema of the optic nerve requires withdrawal of the drug.

Detection of lameness on the background of therapy with Dzhintropin requires careful observation.

It is necessary to change the places of hypodermic injections in connection with the possibility of lipoatrophy development.

Drug Interactions

Glucocorticosteroids (GCS) reduce the stimulating effect of somatropin on growth processes.

The effectiveness of the drug (in terms of final growth) may also be affected by concomitant therapy with other hormones, for example, gonadotropin, anabolic steroids, estrogens and thyroid hormones.

Analogues of the drug Jintropin

Structural analogs for the active substance:

• The biosome;
• Genotropin;
• Dinatrop;
• Norditropin;
• Omnitrop;
• Rastan;
• Sizen;
• Somatropin;
• Somatropin is a human;
• Humatrop.

Similar medicines:

Other medicines: